DRESDEN, GERMANY--(Marketwire - March 31, 2009) - RESprotect GmbH announced that its
anti-cancer drug RP101 is the first small molecule known to bind to
heat shock protein Hsp27 and modulate its effect. High levels of
Hsp27 have been detected in leukemias, osteosarcomas, malignant
melanomas and cancers of pancreatic, breast, ovarian, colon, liver,
kidney, gastric, lung, endometrial and prostate origin. Especially
high levels are observed in metastatic tissues. Hsp27 has
significance in the following tumor cell functions:
* Resistance to treatment with cytotoxic drugs
* Development of metastases
* Prevention of apoptosis
Reports describing the importance of Hsp27 in pathologies are
increasing exponentially. The need for drugs modulating the activity
of this target is rising fast. The fact that the tri-dimensional
structures of human Hsp27 is still not known is challenging.
"RP101 is the first small molecule to modulate hsp27. Impressive
effects of RP101 co-treatment from our two previous studies in
patients with pancreatic cancer are now better understood. RP101
appears to enhance both the sensitivity of responders and
non-responders to chemotherapy" said Prof. Rudolf Fahrig, CEO and
In 2007 RESprotect granted the exclusive rights in the USA and Canada
to develop and commercialize RP101 to SciClone Pharmaceuticals, Inc.
(USA), performing clinical studies with RP101. The results are freely
available to RESprotect.
Enrollment in a randomized, placebo-controlled, double-blind phase 2
clinical trial for RP101 in advanced pancreatic cancer patients has
now been completed.
This study with 153 patients is conducted at 50 study sites
throughout the USA, Europe, and South America. Patients assigned to
the treatment arm are receiving RP101 plus gemcitabine, while
patients in the control arm receive gemcitabine alone. Primary
endpoint for the trial is overall survival.
RP101 is a nucleoside analogue which has been evaluated in
pre-clinical and clinical studies for its potential to prevent
induction of chemo-resistance and enhance chemo-sensitivity. RP101
co-treatment rapidly induces cell death (apoptosis) and suppresses
the expression of genes associated with drug resistance. RP101 has
shown biological activity in broad studies for various cancer
indications suggesting broad activity.
In two separate, unrelated small clinical trials RP101 was used in
combination with gemcitabine or gemcitabine + cisplatin to treat
patients with late-stage pancreatic cancer. The results published
demonstrated that RP101 co-treatment approximately doubled median
survival. In patients with stage IV disease and far metastases who
received co-treatment, the one year survival rate was 67% (40%)
compared to 13% (7%) for patients treated with chemotherapy alone.
RP101 is very well tolerated, with no known side effects.
About RESprotect GmbH
RESprotect GmbH is a privately owned Biotech-Company located in
Dresden/Germany. RESprotect is focusing on unique approaches that
inhibit both chemoresistance and the enhancement of chemosensitivity
RESprotect is looking for partners to develop RP101 in Europe, South
America and Asia and its follow-on compounds worldwide.
Prof. Dr. Rudolf Fahrig
Phone: +49 (351) 450 3200
Fax: +49 (351) 450 3210
Web: http://www.resprotect.com; http://www.rp101.com
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.